Regarding the prescription drug finasteride taken for hair loss: Will FDA approval be revoked by the end of 2023?
11
38
205
resolved Jan 4
Resolved
NO
This market resolves to YES if, as of Dec 31, 2023 at 11:59 pm, the US Food and Drug Administration has revoked approval of finasteride 1 mg/day taken for androgenetic alopecia (male pattern hair loss). Mar 26, 10:02am: A foundation has sued FDA for not responding to a petition requesting that Propecia be removed from the market: https://www.citizen.org/litigation/post-finasteride-syndrome-foundation-v-fda/
Get Ṁ200 play money

🏅 Top traders

#NameTotal profit
1Ṁ77
2Ṁ49
3Ṁ17
4Ṁ14
5Ṁ10
Sort by:

⚠AFK Creator

📢Resolved to NO

PROOF:

National Institute Of Health

bought Ṁ60 of NO

Looks like the FDA responded to this thing by requiring a warning label but not banning it 🤷

sold Ṁ23 of YES

FDA probably won't be moved, but this was published in the NY Post:

https://nypost.com/2022/08/10/georgia-family-blames-propecia-for-sons-suicide/

@marmot CW: upsetting material

bought Ṁ25 of NO
If I'm wrong, can someone please take my money? 🥺
bought Ṁ20 of NO
Can someone tell me why this should happen? I know post-finasteride syndrome is a thing that's plausibly real and poorly understood, but has anything happened recently? Why would the FDA revoke approval over such a thing? On priors (plausible mechanism + people happily using it) I expect it to be effective, is the effectiveness being called into question?

@Ophelia Hi, I'm replying a year later! There was a Citizen Petition pending at the time this question was created. The petition called for taking finasteride for hair loss off the market or adding a black box warning. FDA responded in 2022, nearly 5 years after the petition was submitted. They did not take the drug off the market or add a boxed warning, but they did add a warning about suicidal ideation and behavior as reported by Reuters:

https://www.reuters.com/business/healthcare-pharmaceuticals/fda-requires-disclosure-suicide-risk-anti-baldness-drug-2022-06-10/

Regulators in various countries are reviewing the drug's risks and/or adding warnings (e.g., the UK, France and Canada).